RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
RenovoRx, Inc.NASDAQ: RNXT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 80.1% from a year ago
Other current liabilities stood at $272K at the end of Q1 FY2026, up 80.1% from a year earlier and down 63.6% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Other current liabilities amounted to 1.9% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +80.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 748K USD
- Year-over-year change
- -8.4%
- 4-year CAGR
- +118.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 748K | -8.4% |
| FY2024 | 2024-12-31 | 817K | +989.3% |
| FY2023 | 2023-12-31 | 75K | -84.2% |
| FY2022 | 2022-12-31 | 475K | +1339.4% |
| FY2021 | 2021-12-31 | 33K | — |
Other Current Liabilities vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 other current liabilities of $272K is the lowest of the 6 companies compared; the peer median is $3.72M.
- Its year-over-year change of +80.1% is the 3rd highest of 4, against a peer median of +331.5%.
- Other current liabilities amounts to 1.9% of total assets for RNXT, versus a peer median of 18.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $6.93M | +331.5% | -20.6% | 6.5% | |
| Mar 2026 | $6.78M | +702.9% | +8796105.1% | 41.7% | |
| Mar 2026 | $3.72M | — | +1072.3% | 51.5% | |
| Mar 2026 | $3.55M | — | — | 18.5% | |
| Mar 2026 | $1.51M | +22.9% | +3.1% | 4.3% | |
| Mar 2026 | $272K | +80.1% | +16.3% | 1.9% | |
| Peer median (excluding RNXT) | $3.72M | +331.5% | +537.7% | 18.5% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.